Navigation Links
Oncothyreon reports full year and fourth quarter 2008 financial results
Date:3/9/2009

......... 23,388 212 24,416 528 Licensing, royalties and other revenue............ - 80 - 103 --------- --------- --------- --------- 36,024 1,938 39,998 3,798 --------- --------- --------- --------- Expenses Research and development.............. 2,401 2,278 9,318 10,011 Manufacturing............. 10,527 1,396 13,675 2,564 General and administrative........... 2,444 3,567 9,749 11,797 Marketing and business development.............. - 26 - 565 Amortization.............. 105 84 422 246 Investment and other (income) expense......... (177) (19) (291) 376 Change in fair value of warrant liability........ - (242) - (1,421) --------- --------- --------- --------- 15,300 7,090 32,873 24,138 --------- --------- --------- --------- Net income (loss)........... 20,724 (5,152) 7,125 (20,340) Other comprehensive income.................... - 1,253 - 3,243 --------- --------- --------- --------- Comprehensive net income (loss)..................... $ 20,724 $ (3,899) $ 7,125 $(17,097) --------- --------- --------- --------- --------- --------- --------- --------- Income (loss) per share - Basic...................... $ 1.06 $ (0.26) $ 0.37 $ (1.04)
'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
2. Oncothyreon to present at BIO CEO & Investor Conference 2009
3. Oncothyreon reports third quarter 2008 financial results
4. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at BIO Investor Forum 2008
7. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
8. Oncothyreon announces prioritization plan for development programs
9. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
10. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has ... Market Outlook 2020 " report to their offering. ... regenerative medicine is expected to have huge marketing potential. ... in the growth of deregulated organs. Several therapeutic molecules ... to form new tissue or sometimes organ transplant is ...
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... 2007, Wyeth (NYSE: WYE ) will announce financial ... a one-hour conference call with,research analysts at 7:30 a.m. ... may listen to the call live or on a ... by visiting our website,at http://www.wyeth.com and clicking ...
... China Technology,Development Group Corporation (Nasdaq: CTDC; "CTDC" ... strategy of entering the booming solar energy,sector. ... China,s,use of renewable energy in the coming ... the new business strategy will deliver shareholder,value ...
... 7 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ... Annual Healthcare Conference in New York will be webcast,and ... http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) A member of Human ... the company on Tuesday, September 11, 2007 at 4:00 ...
Cached Biology Technology:China Technology Announces Entry to the Solar Energy Sector 2China Technology Announces Entry to the Solar Energy Sector 3
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... AGA Research Foundation and Horizon Pharma further establish their ... the 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the ... third year, this competition continues to grow in popularity ... in basic and clinical research," said Nicholas F. LaRusso, ...
... declining worldwide and a major cause is a deadly fungus ... shows they can also die from this pathogen, contrary to ... spreads the disease. When researchers raised the frogs from ... strain of this pathogen, Batrachochytrium dendrobatidis , also called ...
... news release is available in French . ... in older mice with Alzheimer,s disease can be reversed with treatment. ... - The Neuro, at McGill University and at Universit de Montral ... brain of mice with advanced Alzheimer,s disease (AD) recovers memory and ...
Cached Biology News:Horizon Pharma Abstract Prizes recognize promising fellows and students 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
... Minidizer is a personal desktop unit ideal for ... requirements. , Rotation speed set at 12 ... 80o C , Bottle capacity of four ... 15 ml conical ,plastic bottles , Consistent, ...
... is the latest edition to the famous ... an extra large diameter exhaust port for ... panel allows precise setting and control of ... handling large quantities and samples , ...
... no-frills, basic SpeedVac concentrator designed for the ... unit still features a standard Teflon coated ... time and heat. It is designed for ... wide variety of different rotors for maximum ...
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
Biology Products: